PubRank

C R Dunstan

Author PubWeight™ 135.61‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 17.76
2 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 15.96
3 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999 12.32
4 osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998 7.81
5 TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999 6.93
6 Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999 5.78
7 RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 2000 3.95
8 The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000 3.38
9 The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999 2.78
10 Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999 2.69
11 Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999 2.69
12 Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999 2.27
13 Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000 2.20
14 Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001 1.83
15 The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001 1.57
16 Bone morphogenetic protein 2 (BMP-2) enhances BMP-3, BMP-4, and bone cell differentiation marker gene expression during the induction of mineralized bone matrix formation in cultures of fetal rat calvarial osteoblasts. Calcif Tissue Int 1997 1.51
17 A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. J Bone Miner Res 1999 1.47
18 Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001 1.44
19 The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 2000 1.43
20 OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 2001 1.41
21 Measurement of bone in the os calcis: a clinical evaluation. J Bone Miner Res 1989 1.39
22 Difficult airway alert. Anaesthesia 2003 1.38
23 Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 1998 1.33
24 E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 1996 1.30
25 The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006 1.25
26 Quantitative bone histology: a new method. Pathology 1980 1.15
27 Bone resorption caused by three periodontal pathogens in vivo in mice is mediated in part by prostaglandin. Infect Immun 1998 1.14
28 Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. J Cell Biochem 1999 1.07
29 Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000 1.03
30 Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 2001 1.03
31 Recovery from steroid-induced osteoporosis. Ann Intern Med 1987 1.01
32 Immobilisation hypercalcemia. Miner Electrolyte Metab 1984 0.97
33 Bone loss after liver transplantation. Hepatology 1991 0.97
34 Lack of metabolic bone disease in patients with fracture of the femoral neck. Aust N Z J Med 1981 0.96
35 Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001 0.96
36 Osteoprotegerin mitigates tail suspension-induced osteopenia. Bone 2000 0.94
37 RANK ligand. Int J Biochem Cell Biol 2006 0.92
38 Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. Mol Ther 2001 0.92
39 Unique microstructural design of ceramic scaffolds for bone regeneration under load. Acta Biomater 2013 0.92
40 Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. Bone 2005 0.91
41 Quantitative bone histology in the hypercalcemia of malignant disease. J Clin Endocrinol Metab 1982 0.90
42 The effect of age on bone composition and viability in the femoral head. J Bone Joint Surg Am 1985 0.90
43 Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. Cancer Res 1997 0.90
44 Effect of aluminum on normal and uremic rats: tissue distribution, vitamin D metabolites, and quantitative bone histology. Calcif Tissue Int 1983 0.88
45 The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin Exp Metastasis 2004 0.88
46 Bone metabolism in chronic renal failure. Miner Electrolyte Metab 1982 0.88
47 Growth retardation and renal osteodystrophy in children with chronic renal failure. J Pediatr 1983 0.84
48 The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women. Osteoporos Int 1993 0.84
49 Repairing a critical-sized bone defect with highly porous modified and unmodified baghdadite scaffolds. Acta Biomater 2012 0.84
50 The pathogenesis of osteoarthritis of the hip. Evidence for primary osteocyte death. Clin Orthop Relat Res 1987 0.83
51 Bone histology in young adult osteoporosis. J Clin Pathol 1989 0.81
52 The determination of bone viability: a histochemical method for identification of lactate dehydrogenase activity in osteocytes in fresh calcified and decalcified sections of human bone. Pathology 1982 0.81
53 Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. J Orthop Res 2001 0.81
54 Quantitative bone histology in children with chronic renal failure. Kidney Int 1982 0.81
55 Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone. Aust N Z J Med 1983 0.81
56 The effects of osteoprotegerin on the mechanical properties of rat bone. J Mater Sci Mater Med 2001 0.80
57 Bone metabolism in systemic mastocytosis. A case report. J Bone Joint Surg Am 1981 0.79
58 Effects of human tumor cell lines on local new bone formation in vivo. Calcif Tissue Int 1997 0.79
59 The effect of long-term low-dose diphosphonate treatment on rat bone. Clin Orthop Relat Res 1982 0.77
60 Effect of aluminum and parathyroid hormone on osteoblasts and bone mineralization in chronic renal failure. Calcif Tissue Int 1984 0.76
61 Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination. Miner Electrolyte Metab 1985 0.76
62 The pathogenesis of idiopathic hypercalciuria: evidence for parathyroid hyperfunction. Q J Med 1984 0.76
63 Adult osteosclerosis. Metab Bone Dis Relat Res 1984 0.76
64 Metabolic studies in kidney stone disease. Q J Med 1992 0.76
65 Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab. Int J Numer Method Biomed Eng 2013 0.76
66 Bone metabolism in idiopathic juvenile osteoporosis: a case report. Calcif Tissue Int 1983 0.75
67 Immobilization hypercalcaemia due to low bone formation and responding to intravenous sodium sulphate. Postgrad Med J 1986 0.75
68 Treatment of Paget's disease of bone with a combination of intranasal salmon calcitonin and oral calcium and thiazide. Calcif Tissue Int 1991 0.75
69 Aluminium-related bone disease presenting with calcaneal stress fractures. Br J Rheumatol 1993 0.75
70 Long-term experience with a calcium-thiazide treatment for Paget's disease of bone. Miner Electrolyte Metab 1982 0.75
71 Mitogenic lectin concanavalin A induces calvarial bone formation in vivo via indomethacin-sensitive pathway. Calcif Tissue Int 1997 0.75
72 Treatment of childhood renal osteodystrophy with calcitriol or ergocalciferol. Clin Nephrol 1985 0.75
73 Aluminum and renal bone disease in Australia. Kidney Int Suppl 1986 0.75
74 Change from continuous epidural infusion to patient-controlled epidural analgesia on the labour ward of a large district general hospital. Int J Obstet Anesth 2006 0.75
75 Quantitative bone histology in end-stage renal failure. Prog Biochem Pharmacol 1980 0.75
76 The pathogenesis of renal osteodystrophy: role of vitamin D, aluminium, parathyroid hormone, calcium and phosphorus. Q J Med 1985 0.75
77 Prurigo nodularis and aluminium overload in maintenance haemodialysis. Lancet 1992 0.75